The CEO Chairman of the Board of Seattle Genetics, Clay B. Siegall, Ph.D., enjoys posting interesting articles on his blog. A new one he just posted is about the possible return of Tasmanian Tigers which were thought to have gone extinct 80 years ago. There have been enough credible sightings reported that researchers at James Cook University in Australia have decided to go see if they can find them. They plan to go to the area where these animals have been reported and set up several cameras in the area in order to get pictures of them.
Another article he posts says that the HPV vaccine, which prevents several types of cancer, can be administered with fewer shots of a vaccine that is more effective. The Centers for Disease Control and other advisory committees said that the number of shots could be reduced to two from the currently recommended three. The shots are given to boys and girls between the ages of 9 and 14.
Dr. Siegall’s career has been focused on founding cures to cancer. His research focuses on antibody-drug conjugates as effective cancer drug therapies. His cancer drug Adcetris was approved by the FDA in 2011 and is now being used in 65 countries around the world.
In 2016, Dr. Seigall conducted an interview with the Puget Sound Business Journal. During the interview, he said that he plans to add another 12 cancer drugs to the pipeline at Seattle Genetics over the next year. He also plans to widen the use of Adcetris to treat additional forms of cancer such as Hodgkin Lymphoma.
Dr. Siegall also stated that he has another drug, currently called 33A, that entered the crucial Phase 3 clinical trials in 2016. 33A was created to treat acute myeloid leukemia. Two other cancer drugs that could enter Phase 3 includes one for breast cancer and two that are for treating bladder cancer.
In order to support the growing amount of drugs under development, Dr. Siegall said that he was looking to hire another 120 employs between the company’s locations in Bothell, Washington and its office in Switzerland.